630421-77-1Relevant articles and documents
Hepatitis C virus inhibitors
-
Page/Page column 44, (2008/06/13)
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 56; 57, (2010/02/11)
Compounds are disclosed having general formula (I), wherein R1, R2, R3, R4, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.